---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000031"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:22:46.570747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Praxis reports positive EMBRAVE Part A data for elsunersen; FDA grants priority review for relutrigine

## Summary
- Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in 9-patient Phase 1/2 trial.
- 57% of elsunersen patients had ≥28-day seizure freedom; improvements in sleep, motor function, attention.
- Relutrigine NDA accepted for priority review by FDA with PDUFA target date of September 27, 2026.
- Elsunersen well tolerated; no drug-related SAEs, no discontinuations, no neuroinflammation at doses up to 8 mg.
- All 9 patients continued into open-label extension; efficacy sustained for up to one year.

## SEC filing metadata
- accession: 0001689548-26-000031
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/0001689548-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000031
- JSON: https://secwatch.observer/filing/0001689548-26-000031.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.